top of page

Big News in Polycythemia Vera (High Red Cells)

Amit Garg
3 days ago
1 min read

Rusfertide (Mimrylo) was approved by the FDA 9/28/2026. It is a first-in-class hepcidin mimetic designed to control erythrocytosis (high red cells) in patients with polycythemia vera (PV). It is given as a once-weekly subcutaneous injection


Unlike hydroxyurea, interferon, or JAK inhibitors, rusfertide works by regulating iron availability for red blood cell production.


It's exciting because rusfertide may offer patients better hematocrit control, less phlebotomies, and less fatigue.


How does it work?

PV causes excessive red blood cell production, increasing blood viscosity and thrombotic risk.

Rusfertide mimics hepcidin, the hormone that regulates iron metabolism. It reduces iron export through ferroportin, limiting iron availability for red cell production and less phlebotomies


Why is this helpful?

Many patients with PV require regular phlebotomies to maintain hematocrit below 45%.

Repeated phlebotomies can cause iron deficiency resulting in fatigue, restless legs, and other symptoms.


What did the phase III VERIFY trial show?

The VERIFY trial enrolled 293 adults with PV who required frequent phlebotomies despite current treatment.

Patients received rusfertide or placebo in addition to their existing therapy.

Rusfertide + standard care 76.9%

Placebo + standard care 32.9%

Achieved the primary response endpoint


The primary endpoint was avoiding protocol-defined phlebotomy eligibility during weeks 20–32. Rusfertide more than doubled the response rate.


Why did Takeda recently announce?

On 11/12/2026, Takeda announced six rusfertide abstracts for ASH 2026 in December, including analyses of:

  • Patient-reported symptoms and quality of life.

  • Reduction in phlebotomy burden.

  • Efficacy and safety across different patient subgroups.





 
 
 

Recent Posts

See All
5 Lab clues you are Iron Deficient

 1. Ferritin<30 ng/mL. Ferritin<100 ng/mL if inflammation, autoimmune diseases, cancer 2. Low transferrin saturation (TSAT) <20% suggests insufficient circulating iron availability 3. MCV <80 indicate

 
 
 
New prostate cancer screening guidelines

The American Cancer Society (ACS) announced a major change in prostate cancer screening recommendations 11/12/2026, its first update since 2010. The ACS now recommends routine PSA blood testing, rathe

 
 
 

3 Comments


kimbrincklow
3 days ago

My daughter has PV, is taking interferon every 2 weeks, is not having to have blood draws and has stable H&H. Her ferritin level was 7 but now is only 5. She feels pretty weak, but is still working from home and taking care of her teens. One oncologist wants her to have aniron infusion but her PV says no. Could this med be helpful to her so she could have a higher ferritin and maybe feel better?

Like
Amit Garg
3 days ago
Replying to

The exciting part about rusfertide is iron levels normalize over time and patients are less tired. Talk to her hematologist. Take care.

Like
bottom of page